This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clincial Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 21 open trials.
In 121 locations
What is a Clinical Trial?
There are currently 21 open trials
- MUK nine b: OPTIMUM
- CAR T cell therapy for relapsed and/or refractory myeloma (AUTO2 trial)
- Melflufen and dexamethasone in myleoma patients refractory to lenalidomide (OCEAN trial)
- TAS-120 for refractory myeloma patients with FGF/FGFR abnormalities
- Carfilzomib, thalidomide and dexamethasone in relapsed AL amyloidosis (CATALYST trial)
- Isatuximab in combination with pomalidomide and dexamethasone (ICARIA-MM trial)
- CC-220 monotherapy and combination for relapsed and refractory myeloma patients
- MUK eleven (Reolysin trial)
- Myeloma XII (ACCoRd)
- Venetoclax in combination with bortezomib and dexamethasone
- Durvalumab and daratumumab for relapsed and refractory myeloma patients (FUSIONMM-003 trial)
- Ixazomib and dexamethasone for relapsed or refractory AL amyloidosis patients (TOURMALINE-AL1)
- Buparlisib in combination with bortezomib (BUBBLE trial)
- Early access treatment with daratumumab
- MUK seven
- MUK eight
- Daratumumab combination for newly diagnosed myeloma patients
- Carfilzomib for newly diagnosed patients prior to stem cell transplant (CARDAMON trial)
- Bendamustine combination for newly diagnosed myeloma patients with kidney impairment (OPTIMAL trial)
- GSK2857916 trial
- GSK525762 trial
Trial Title:
MUK nine b: OPTIMUM
Treatments:
Bortezomib (Velcade®)
Dexamethasone
Daratumumab (Darzalex®)
Dexamethasone
Cyclophosphamide
Myeloma stage:
High risk myeloma
Trial phase:
II
Summary:
The aim of this study is to determine whether a combination of bortezomib, lenalidomide, Daratumumab and dexamethasone, together with low-dose cyclophosphamide, is effective as a treatment for patients with high risk myeloma.
Locations:
The Royal Marsden Hospital, Sutton;
Barts Health NHS Trust, London;
Leeds Teaching Hospitals NHS Trust, Leeds;
King's College Hospital, London;
Southampton General Hospital, Southampton;
Guy's Hospital, London;
University Hospitals of Leicester NHS Trust;
University Hospitals Bristol NHS Foundation Trust;
Queen Elizabeth Hospital, Birmingham;
Heartlands Hospital, Birmingham;
Manchester Royal Infirmary, Manchester;
Belfast City Hospital, Northern Ireland;
Ninewells Hospital, Dundee;
The Beatson Institute, Glasgow;
Addenbrooke's Hospital, Cambridge;
Oxford Radcliffe Hospital, Oxford;
Nottingham University Hospitals NHS Trust
Who can enter the study?:
This trial is for patients who have been classified as having high risk myeloma by the Institute of Cancer Research (ICR) through the MUK nine a screening protocol. This includes identification of biomarkers, including genetic, epigenetic or protein markers that are associated with a poor prognosis and response to treatment.
What's involved?:
All patients enrolled in this trail with receive the following treatment:
- Induction: 6 x 21 day cycle
Cyclophosphamide (500mg) is taken by mouth on days 1 and 8 of cycle, and lenalidomide (25mg) on days 1 -14. Bortezomib (1.3mg/m2 ) is given by subcutaneous injection and dexamethasone (20-40mg) is taken by mouth, or intravenously (into the vein) on days 1, 4, 8 and 11. During cycle 1 and 2, Daratumumab (16mg/kg) is given intravenously on days 1, 8 and 15, and during cycles 3 – 6 it is given on day 1 only.
- Autologous stem cell transplant (ASCT)
- Consolidation part 1: 6 x 28 day cycle
Lenalidomide (25mg) is taken by mouth on days 1 – 21 of the cycle, and dexamethasone (20-40mg) on days 1, 8, 15 and 22. Bortezomib (1.3mg/m2 ) is given by subcutaneous injection on days 1, 8, 15 and 22. Daratumumab (16mg/kg) is given intravenously on day 1 of cycle.
- Consolidation part 2: 12 x 28 day cycle
Lenalidomide (25mg) is taken by mouth on days 1 – 21 of cycle. Bortezomib (1.3mg/m2 ) is given by subcutaneous injection on days 1, 8 and 15 and Daratumumab (16mg/kg) is given intravenously on day 1 of cycle.
- Maintenance treatment: 28 day cycle until signs of disease progression
Lenalidomide (10mg) is taken by mouth on days 1 – 21 of cycle, and Daratumumab
Patients are required to visit the outpatient clinic for regular blood test and check-ups.
Clinical Information
(for Medical Professionals):
The purpose of this study is to determine whether a combination of bortezomib, lenalidomide, daratumumab and dexamethasone, together with low-dose cyclophosphamide, is sufficiently active in high risk myeloma to progress to a Phase III trial, where it can be compared to standard treatments.
For more information, click here
Find out more: